2025年6月24日 周二
首页 > 按月查看>2022年第12月 >1071-1076. DOI:10.20039/j.cnki.10073949.2022.12.010
PDF 导出
沙库巴曲缬沙坦治疗心血管疾病的研究进展
作者:
作者单位:

(1.山西医科大学第二临床医学院心血管内科,山西省太原市 030000;2.山西医科大学第二医院心血管内科,山西省太原市 030000;3.太原市杏花岭区中心医院内科,山西省太原市 030000)

作者简介:

张玥,硕士研究生,研究方向为冠心病的基础与临床,E-mail:m13935182638@163.com。通信作者边云飞,博士,教授,研究方向为冠心病的基础与临床,E-mail:410402390@qq.com。

基金项目:

国家自然科学基金项目(820722039)


Research progress of sacubitril/valsartan in the treatment of cardiovascular diseases
Author:
Affiliation:

1.Department of Cardiovascular Medicine, Second Clinical School of Medicine, Shanxi Medical University, ;2.Department of Cardiovascular Medicine, Second Hospital of Shanxi Medical University, ;3.Department of Internal Medicine, Central Hospital of Xinghualing District of Taiyuan City, Taiyuan, Shanxi 030000, China)

  • 摘要
    • | |
  • 访问统计
    • |
  • 参考文献
    • |
  • 相似文献
    • | |
    摘要:

    沙库巴曲缬沙坦是首个血管紧张素受体脑啡肽酶抑制剂,可同时抑制脑啡肽酶和阻断血管紧张素受体。《中国心力衰竭诊断和治疗指南2018》对沙库巴曲缬沙坦作了超越欧洲和美国指南的Ⅰ类推荐。2021年美国食品和药品管理局将沙库巴曲缬沙坦批准用于治疗射血分数正常的心力衰竭患者。大量研究显示沙库巴曲缬沙坦在心力衰竭、心肌梗死、心律失常、高血压、慢性肾脏病和糖尿病患者中均发挥有益作用。本文综述了沙库巴曲缬沙坦治疗心血管疾病及其相关疾病的应用进展。

    Abstract:

    Sacubitril/valsartan is the first angiotensin receptor neprilysin inhibitor that simultaneously inhibits neprilysin and blocks angiotensin receptor. “Guidelines for the Diagnosis and Treatment of Heart Failure in China 2018” made a class Ⅰ recommendation for sacubitril/valsartan that surpassed European and American guidelines. 2021 US Food And Drug Administration approves sacubitril/valsartan for the treatment of heart failure patients with normal ejection fraction. Numerous studies have shown beneficial effects of sacubitril/valsartan in patients with heart failure, myocardial infarction, arrhythmia, hypertension, chronic kidney disease and diabetes. This article reviews the application progress of sacubitril/valsartan in the treatment of cardiovascular disease and related diseases.

    参考文献
    [1] ROTH G A, JOHNSON C, ABAJOBIR A, et al.Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015.J Am Coll Cardiol, 7,0(1):1-25.
    [2] POLONIA J, GONCALVES F R.The historical evolution of knowledge of the involvement of neurohormonal systems in the pathophysiology and treatment of heart failure.Rev Port Cardiol, 9,8(12):883-895.
    [3] REED B N, STREET S E, JENSEN B C.Time and technology will tell:the pathophysiologic basis of neurohormonal modulation in heart failure.Heart Fail Clin, 4,0(4):543-557.
    [4] 刘岳, 汪芳.沙库巴曲缬沙坦的药代动力学和药效学特点.中国循环杂志, 8,3(2):198-200.LIU Y, WANG F.Pharmacokinetic and pharmacodynamic characteristics of sakubatril valsartan.Chin Circ J, 8,3(2):198-200.
    [5] 中华医学会心血管病学分会心力衰竭学组, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018.中华心血管病杂志, 8,6(10):760-789.HEART FAILURE GROUP OF CHINSES SOCIETY OF CARDIOLOGY OF CHINSES MEDICAL ASSOCIATION, CHINSES HEART FAILURE ASSOCIATION OF CHINSES MEDICAL DOCTOR ASSOCIATION, EDITORIAL BOARD OF CHINSES JOURNAR OF CARDIOLOY.Guidelines for the diagnosis and treatment of heart failure in China 2018.Chin J Cardiol, 8,6(10):760-789.
    [6] VON LUEDER T G, WANG B H, KOMPA A R, et al.Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy.Circ Heart Fail, 5,8(1):71-78.
    [7] SEKI T, GOTO K, KANSUI Y, et al.Angiotensin II receptor-neprilysin inhibitor sacubitril/valsartan improves endothelial dysfunction in spontaneously hypertensive rats.J Am Heart Assoc, 7,6(10):e006617.
    [8] MCMURRAY J J, PACKER M, DESAI A S, et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure.N Engl J Med, 4,1(11):993-1004.
    [9] VELAZQUEZ E J, MORROW D A, DEVORE A D, et al.Angiotensin-neprilysin inhibition in acute decompensated heart failure.N Engl J Med, 9,0(6):539-548.
    [10] WACHTER R, SENNI M, BELOHLAVEK J, et al.Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge:primary results of the randomised transition study.Eur J Heart Fail, 9,1(8):998-1007.
    [11] WANG Y, ZHOU R, LU C, et al.Effects of the angiotensin-receptor neprilysin inhibitor on cardiac reverse remodeling:Meta-analysis.J Am Heart Assoc, 9,8(13):e012272.
    [12] MADDOX T M, JANUZZI J L J R , ALLEN L A, et al.2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment:answers to 10 pivotal issues about heart failure with reduced ejection fraction:a report of the American College of Cardiology Solution Set Oversight Committee.J Am Coll Cardiol, 1,7(6):772-810.
    [13] JANUZZI J L J R, PRESCOTT M F, BUTLER J, et al.Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction.JAMA, 9,2(11):1085-1095.
    [14] MANN D L, GREENE S J, GIVERTZ M M, et al.Sacubitril/valsartan in advanced heart failure with reduced ejection fraction:rationale and design of the life trial.JACC Heart Fail, 0,8(10):789-799.
    [15] PONIKOWSKI P, VOORS A A, ANKER S D, et al.2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure:the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC.Eur J Heart Fail, 6,8(8):891-975.
    [16] SOLOMON S D, ZILE M, PIESKE B, et al.The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction:a phase 2 double-blind randomised controlled trial.Lancet, 2,0(9851):1387-1395.
    [17] SOLOMON S D, MCMURRAY J J V, ANAND I S, et al.Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction.N Engl J Med, 9,1(17):1609-1620.
    [18] WACHTER R, SHAH S J, COWIE M R, et al.Angiotensin receptor neprilysin inhibition versus individualized raas blockade:design and rationale of the parallax trial.ESC Heart Fail, 0,7(3):856-864.
    [19] ISHII M, KAIKITA K, SATO K, et al.Cardioprotective effects of LCZ696 (sacubitril/valsartan) after experimental acute myocardial infarction.JACC Basic Transl Sci, 7,2(6):655-668.
    [20] ZHANG H, LIU G Q, ZHOU W P, et al.Neprilysin inhibitor-angiotensin II receptor blocker combination therapy (sacubitril/valsartan) suppresses atherosclerotic plaque formation and inhibits inflammation in apolipoprotein E-deficient mice.Sci Rep, 9,9(1):6509.
    [21] TORRADO J, CAIN C, MAURO A G, et al.Sacubitril/valsartan averts adverse post-infarction ventricular remodeling and preserves systolic function in rabbits.J Am Coll Cardiol, 8,2(19):2342-2356.
    [22] REZQ A, SAAD M, EL NOZAHI M.Comparison of the efficacy and safety of sacubitril/valsartan versus ramipril in patients with ST-segment elevation myocardial infarction.Am J Cardiol, 1,3:7-13.
    [23] PFEFFER M A, CLAGGETT B, LEWIS E F, et al.Angiotensin receptor-neprilysin inhibition in acute myocardial infarction.N Engl J Med, 1,5(20):1845-1855.
    [24] ALVAREZ C K, CRONIN E, BAKER W L, et al.Heart failure as a substrate and trigger for ventricular tachycardia.J Interv Card Electrophysiol, 9,6(3):229-247.
    [25] DESAI A S, MCMURRAY J J, PACKER M, et al.Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients.Eur Heart J, 5,6(30):1990-1997.
    [26] MARTENS P, NUYENS D, RIVERO-AYERZA M, et al.Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.Clin Res Cardiol, 9,8(10):1074-1082.
    [27] CHANG P C, LIN S F, CHU Y, et al.LCZ696 therapy reduces ventricular tachyarrhythmia inducibility in a myocardial infarction-induced heart failure rat model.Cardiovasc Ther, 9,9:6032631.
    [28] SEFEROVIC J P, CLAGGETT B, SEIDELMANN S B, et al.Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes:a post-hoc analysis from the PARADIGM-HF trial.Lancet Diabetes Endocrinol, 7,5(5):333-340.
    [29] DE DIEGO C, GONZALEZ-TORRES L, NUNEZ J M, et al.Effects of angiotensin-neprilysin inhibition compared to angiotensin inhibition on ventricular arrhythmias in reduced ejection fraction patients under continuous remote monitoring of implantable defibrillator devices.Heart Rhythm, 8,5(3):395-402.
    [30] VICENT L, MENDEZ-ZURITA F, VINOLAS X, et al.Clinical characteristics of patients with sustained ventricular arrhythmias after sacubitril/valsartan initiation.Heart Vessels, 0,5(1):136-142.
    [31] RUILOPE L M, DUKAT A, BOHM M, et al.Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin:a randomised, double-blind, placebo-controlled, active comparator study.Lancet, 0,5(9722):1255-1266.
    [32] NIE D, XIONG B, QIAN J, et al.The effect of sacubitril-valsartan in heart failure patients with mid-range and preserved ejection fraction:a Meta-analysis.Heart Lung Circ, 1,0(5):683-691.
    [33] HUO Y, LI W, WEBB R, et al.Efficacy and safety of sacubitril/valsartan compared with olmesartan in asian patients with essential hypertension:a randomized, doubleblind, 8-week study.J Clin Hypertens (Greenwich), 9,1(1):67-76.
    [34] KARIO K, SUN N, CHIANG F T, et al.Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension:a randomized, double-blind, placebo-controlled study.Hypertension, 4,3(4):698-705.
    [35] DAMMAN K, VALENTE M A, VOORS A A, et al.Renal impairment, worsening renal function, and outcome in patients with heart failure:an updated Meta-analysis.Eur Heart J, 4,5(7):455-469.
    [36] MOHANY M, ALANAZI A Z, ALQAHTANI F, et al.LCZ696 mitigates diabetic-induced nephropathy through inhibiting oxidative stress, NF-κB mediated inflammation and glomerulosclerosis in rats.PeerJ, 0,8:e9196.
    [37] SABBAH H N, ZHANG K, GUPTA R C, et al.Effects of angiotensin-neprilysin inhibition in canines with experimentally induced cardiorenal syndrome.J Card Fail, 0,6(11):987-997.
    [38] HAYNES R, JUDGE P K, STAPLIN N, et al.Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease.Circulation, 8,8(15):1505-1514.
    [39] DAMMAN K, GORI M, CLAGGETT B, et al.Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure.JACC Heart Fail, 8,6(6):489-498.
    [40] MC CAUSLAND F R, LEFKOWITZ M P, CLAGGETT B, et al.Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction.Circulation, 0,2(13):1236-1245.
    [41] 孙学娇, 刘乃丰.关注糖尿病与血管钙化的共同发病机制和临床意义.中国动脉硬化杂志, 0,8(2):169-174.SUN X J, LIU N F.Focus on the common pathogenesis and clinical significance of diabetes mellitus and vascular calcification.Chin J Arterioscler, 0,8(2):169-174.
    [42] KRISTENSEN S L, PREISS D, JHUND P S, et al.Risk related to pre-diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction:insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial.Circ Heart Fail, 6,9(1):e002560.
    [43] KHAN M S, FELKER G M, PINA I L, et al.Reverse cardiac remodeling following initiation of sacubitril/valsartan in patients with heart failure with and without diabetes.JACC Heart Fail, 1,9(2):137-145.
    [44] MOULIS F, ROUSSEAU V, CHEBANE L, et al.Serious adverse drug reactions with sacubitril/valsartan Entresto:a French pharmacovigilance survey.Eur J Clin Pharmacol, 8,4(7):983-984.
    [45] AYALASOMAYAJULA S, LANGENICKEL T, PAL P, et al.Clinical pharmacokinetics of sacubitril/valsartan (LCZ696):a novel angiotensin receptor-neprilysin inhibitor.Clin Pharmacokinet, 7,6(12):1461-1478.
    引证文献
引用本文

张玥,边云飞,郭旭男,杨志美.沙库巴曲缬沙坦治疗心血管疾病的研究进展[J].中国动脉硬化杂志,2022,30(12):1071~1076.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:2021-03-19
  • 最后修改日期:2021-10-08
  • 在线发布日期: 2022-12-13

您是本站第 4902717 访问者

邮编：421001 传真：0734-8160523

电话：0734-8160765 E-mail：dmzzbjb@163.net

中国动脉硬化杂志 ® 2025 网站版权所有